BOSTON, Nov. 14, 2022 /PRNewswire/ — Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, today announced that its lead candidate for idiopathic pulmonary fibrosis (IPF), TXR-1002, demonstrated significant efficacy in new preclinical research. TXR-1002 represents a completely new novel mechanism of action for the potential treatment of IPF. Data was presented at the 6th Annual Antifibrotic Drug Development Summit on November 10 in Boston.

Read more here.